,address1,address2,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,140 Intracoastal Pointe Drive,Suite 404,Jupiter,FL,33477-5094,United States,561 743 8333,561 743 8343,https://www.dyadic.com,Biotechnology,Healthcare,"Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., as well as co-development and marketing agreement with Fermbox Bio Inc to design, Develop, and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter, Florida.","{'maxAge': 1, 'name': 'Mr. Mark A. Emalfarb', 'age': 66, 'title': 'Founder, CEO, Pres & Director', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 636611, 'exercisedValue': 0, 'unexercisedValue': 0}",8,6,8,9,7,1693526400,1672444800,86400,4,1.82,1.79,1.75,1.86,1.82,1.79,1.75,1.86,0.0,0.594052,14.583334,21863,21863,17387,14510,14510,1.61,1.96,800,1100,50419424,1.12,2.4,14.663058,1.8464,1.72325,0.0,0.0,USD,42307216,-2.05465,18701548,28811100,410049,405768,1690761600,1693440000,0.014199999,0.30065,0.16069001,23.49,0.0202,0.312,5.6089745,1672444800,1703980800,1688083200,-7065002,-0.25,0.12,12.304,NCM,EQUITY,DYAI,DYAI,"Dyadic International, Inc.","Dyadic International, Inc.",1200493800,America/New_York,EDT,-14400000,1.75,9.0,6.0,7.5,7.5,2.0,buy,2,10128916,0.352,0,5.464,5.532,3438534,0.12,-0.37012002,-0.62669,807110,-4634990,-7299629,0.271,0.17778999,0.0,-2.43676,USD,
1,140 Intracoastal Pointe Drive,Suite 404,Jupiter,FL,33477-5094,United States,561 743 8333,561 743 8343,https://www.dyadic.com,Biotechnology,Healthcare,"Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., as well as co-development and marketing agreement with Fermbox Bio Inc to design, Develop, and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter, Florida.","{'maxAge': 1, 'name': 'Ms. Ping Wang Rawson CPA, M.B.A.', 'age': 46, 'title': 'Chief Financial Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 279070, 'exercisedValue': 0, 'unexercisedValue': 0}",8,6,8,9,7,1693526400,1672444800,86400,4,1.82,1.79,1.75,1.86,1.82,1.79,1.75,1.86,0.0,0.594052,14.583334,21863,21863,17387,14510,14510,1.61,1.96,800,1100,50419424,1.12,2.4,14.663058,1.8464,1.72325,0.0,0.0,USD,42307216,-2.05465,18701548,28811100,410049,405768,1690761600,1693440000,0.014199999,0.30065,0.16069001,23.49,0.0202,0.312,5.6089745,1672444800,1703980800,1688083200,-7065002,-0.25,0.12,12.304,NCM,EQUITY,DYAI,DYAI,"Dyadic International, Inc.","Dyadic International, Inc.",1200493800,America/New_York,EDT,-14400000,1.75,9.0,6.0,7.5,7.5,2.0,buy,2,10128916,0.352,0,5.464,5.532,3438534,0.12,-0.37012002,-0.62669,807110,-4634990,-7299629,0.271,0.17778999,0.0,-2.43676,USD,
2,140 Intracoastal Pointe Drive,Suite 404,Jupiter,FL,33477-5094,United States,561 743 8333,561 743 8343,https://www.dyadic.com,Biotechnology,Healthcare,"Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., as well as co-development and marketing agreement with Fermbox Bio Inc to design, Develop, and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter, Florida.","{'maxAge': 1, 'name': 'Mr. Joseph P. Hazelton', 'title': 'Chief Bus. Officer', 'fiscalYear': 2022, 'totalPay': 276854, 'exercisedValue': 0, 'unexercisedValue': 0}",8,6,8,9,7,1693526400,1672444800,86400,4,1.82,1.79,1.75,1.86,1.82,1.79,1.75,1.86,0.0,0.594052,14.583334,21863,21863,17387,14510,14510,1.61,1.96,800,1100,50419424,1.12,2.4,14.663058,1.8464,1.72325,0.0,0.0,USD,42307216,-2.05465,18701548,28811100,410049,405768,1690761600,1693440000,0.014199999,0.30065,0.16069001,23.49,0.0202,0.312,5.6089745,1672444800,1703980800,1688083200,-7065002,-0.25,0.12,12.304,NCM,EQUITY,DYAI,DYAI,"Dyadic International, Inc.","Dyadic International, Inc.",1200493800,America/New_York,EDT,-14400000,1.75,9.0,6.0,7.5,7.5,2.0,buy,2,10128916,0.352,0,5.464,5.532,3438534,0.12,-0.37012002,-0.62669,807110,-4634990,-7299629,0.271,0.17778999,0.0,-2.43676,USD,
3,140 Intracoastal Pointe Drive,Suite 404,Jupiter,FL,33477-5094,United States,561 743 8333,561 743 8343,https://www.dyadic.com,Biotechnology,Healthcare,"Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., as well as co-development and marketing agreement with Fermbox Bio Inc to design, Develop, and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter, Florida.","{'maxAge': 1, 'name': 'Ms. Ana GÃ³mez Rodriguez', 'title': 'Sec. of the Board', 'exercisedValue': 0, 'unexercisedValue': 0}",8,6,8,9,7,1693526400,1672444800,86400,4,1.82,1.79,1.75,1.86,1.82,1.79,1.75,1.86,0.0,0.594052,14.583334,21863,21863,17387,14510,14510,1.61,1.96,800,1100,50419424,1.12,2.4,14.663058,1.8464,1.72325,0.0,0.0,USD,42307216,-2.05465,18701548,28811100,410049,405768,1690761600,1693440000,0.014199999,0.30065,0.16069001,23.49,0.0202,0.312,5.6089745,1672444800,1703980800,1688083200,-7065002,-0.25,0.12,12.304,NCM,EQUITY,DYAI,DYAI,"Dyadic International, Inc.","Dyadic International, Inc.",1200493800,America/New_York,EDT,-14400000,1.75,9.0,6.0,7.5,7.5,2.0,buy,2,10128916,0.352,0,5.464,5.532,3438534,0.12,-0.37012002,-0.62669,807110,-4634990,-7299629,0.271,0.17778999,0.0,-2.43676,USD,
